Preferred Slow-Release IV Iron Preparation for RLS
For iron-deficiency restless legs syndrome, ferric carboxymaltose is the preferred slow-release intravenous iron preparation over iron sucrose, administered as a single 1000 mg dose. 1
Why Ferric Carboxymaltose Over Iron Sucrose
The 2025 AASM guidelines provide a strong recommendation for IV ferric carboxymaltose in adults with RLS and appropriate iron status (ferritin ≤75 ng/mL or ferritin 75-100 ng/mL), based on moderate certainty evidence from multiple placebo-controlled RCTs. 1
In contrast, iron sucrose is explicitly not recommended for RLS. The guidelines note that high-quality studies of IV iron sucrose failed to show clinically significant benefit over placebo. 1 The critical pharmacologic difference is that iron sucrose is a fast-release, low-dose formulation that lacks the necessary H-ferritin binding and macrophage iron uptake required for iron penetration into the central nervous system—the key therapeutic target in RLS. 1
The slow-release formulations (ferric carboxymaltose, low-molecular weight iron dextran, ferumoxytol, and ferric derisomaltose) allow higher single doses with superior CNS penetration. 1
Recommended Dosing Schedule
Single dose: 1000 mg IV ferric carboxymaltose administered as a one-time infusion. 2, 3, 4
Administration Details:
- Dilution: Can be given undiluted or diluted in normal saline
- Infusion time: Typically 15-30 minutes for the full 1000 mg dose
- Timing of response: Clinical improvement may begin as early as day 8, but full therapeutic effect often requires 12 weeks 2, 5
- Repeat dosing: May be repeated if iron deficiency recurs or symptoms return
Important Caveats:
Iron parameters for treatment initiation (different from general population): 1
- Treat if ferritin ≤75 ng/mL OR transferrin saturation <20%
- Consider treatment even if ferritin is 75-100 ng/mL
- Target ferritin >100 ng/mL 6
Predictors of response: 7
- Transferrin saturation ≤35% is the most sensitive predictor of favorable response (more so than ferritin alone)
- Lower baseline serum iron and %TSAT predict better response, particularly in females
- Response rates: 64.7% in primary RLS, higher in secondary RLS with iron deficiency anemia (91.3%)
Common pitfall: The initial RCT by Cho et al. (2017) showed only nonsignificant improvement at week 4, reaching significance by week 12. 2 This delayed response means clinicians should not prematurely conclude treatment failure if symptoms don't improve within the first month. Wait at least 12 weeks before assessing efficacy.
Adverse effects: Generally mild, most commonly transient hypophosphatemia. 3 No significant difference in serious adverse events compared to placebo or oral iron. 4, 8
Alternative Slow-Release Formulations
If ferric carboxymaltose is unavailable:
- Low-molecular weight iron dextran (conditional recommendation, very low certainty evidence) 1
- Ferumoxytol (conditional recommendation, very low certainty evidence) 1
These receive only conditional recommendations due to limited evidence (single observational studies), but their pharmacologic properties are similar to ferric carboxymaltose. 1